Please wait...
70
124
Offers Claimed: 197
Downloaded Today: 176
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Commonly reported side effects of repaglinide include: hypoglycemia. See below for a comprehensive list of adverse effects.
For the ConsumerApplies to repaglinide: oral tablet
Along with its needed effects, repaglinide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking repaglinide:
More common
Less common
Incidence not known
Some side effects of repaglinide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
Less common
Incidence not known
For Healthcare Professionals
Applies to repaglinide: oral tablet
GeneralThe most frequently reported adverse reactions were changes in blood glucose levels; the occurrence of these reactions was dependent on individual factors such as dietary habits, dose, exercise, and stress.
MetabolicVery common (10% or more): Hypoglycemia (up to 31%)
In 12 to 24 week clinical trials, hypoglycemia occurred in 31% of patients receiving this drug compared to 7% of placebo-treated patients. In 1 year trials, hypoglycemia occurred in 16% of patients receiving this drug compared to 19% and 20% of glipizide and glyburide patients, respectively.
CardiovascularCardiovascular events were evaluated in trials comparing this drug to sulfonylureas. Serious cardiovascular events including ischemia with this drug were higher at 4% than for sulfonylurea drugs (3%). No excess mortality was associated with this increase. Selected cardiovascular events including hypertension, abnormal EKG, MI, arrhythmias, and palpitations were observed at 1% or less and no more frequently with this drug than with comparator drugs.
Trials of this drug in combination with NPH insulin found 6 serious events of myocardial ischemia.
Common (1% to 10%): Chest pain, angina, serious cardiovascular events including ischemia
Frequency not reported: Hypertension, abnormal EKG, MI, arrhythmias, palpitations
HypersensitivityCommon (1% to 10%): Allergy
Uncommon (0.1% to 1%): Allergic skin reactions such as rash, urticaria, and pruritus
Frequency not reported: Anaphylactoid reactions
Anaphylactoid reactions were reported in less than 1% of patients. Allergic skin reactions such as rash, urticaria, and pruritus have been observed. There is no reason to suspect cross-allergenicity with sulfonylurea drugs due to the difference in chemical structure.
GastrointestinalCommon (1% to 10%): Nausea, diarrhea, constipation, vomiting, dyspepsia, tooth disorder
Postmarketing reports: Pancreatitis
Nervous systemVery common (10% or more): Headache (up to 11%)
Common (1% to 10%): Paresthesia
MusculoskeletalCommon (1% to 10%): Arthralgia, back pain
RespiratoryVery common (10% or more): Upper respiratory infection (up to 16%)
Common (1% to 10%): Sinusitis, rhinitis, bronchitis
HepaticPostmarketing experience has included reports of severe hepatic dysfunction including jaundice and hepatitis.
Frequency not reported: Elevated liver enzymes
Postmarketing reports: Severe hepatic dysfunction including jaundice and hepatitis
HematologicThrombocytopenia or leukopenia have been reported in less than 1% of patients.
Frequency not reported: Thrombocytopenia, leukopenia
Postmarketing reports: Hemolytic anemia
OcularRare (less than 0.1%): Blurred vision
Very rare (less than 0.01%): Refraction disorder
Refraction disorders have been known to result due to changes in blood glucose levels.
DermatologicPostmarketing reports: Alopecia, Stevens-Johnson syndrome
GenitourinaryCommon (1% to 10%): Urinary tract infection
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.
Source: Drugs.com Repaglinide (www.drugs.com/mtm/repaglinide.html).
May 24, 2022
May 24, 2022
May 24, 2022
May 23, 2022
May 23, 2022
May 23, 2022